Evidence map›Paper›PMID 32395138›Full record

ArticleJournal of contemporary brachytherapy2020

Inter-observer and intra-observer variability in reporting vaginal dose points for cervical cancer in high-dose-rate brachytherapy.

Nuria Carrasco, Jose Chimeno, Mar Adrià-Mora, María José Pérez-Calatayud, Blanca Ibáñez, Vicente Carmona, Francisco Celada, Jose Gimeno, Françoise Lliso, José Pérez-Calatayud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of contemporary brachytherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nuria CarrascoRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Jose ChimenoRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Mar Adrià-MoraRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
María José Pérez-CalatayudRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Blanca IbáñezRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Vicente CarmonaRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Francisco CeladaRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Jose GimenoRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
Françoise LlisoRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
José Pérez-CalatayudRadiotherapy Department, La Fe Polytechnic and University Hospital, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe ICRU 89 recommends reporting a set of vaginal dose points for cervical cancer treatments in order to quantify the goodness of implant. This vaginal dose reporting method for combined external beam radiotherapy and brachytherapy has been adopted by the EMBRACE II study protocol. Large variations in dose between patients and centers have been reported. The aim of this study was to determine possible discrepancies with consensus observers from the same institution. Therefore, the inter- and intra-observer variability were analyzed. MATERIAL AND

methodsFor five patients, five experienced observers reported dose at the proposed vaginal points twice. The effect of inter- and intra-observer variations on total dose was analyzed by estimating biologically equivalent dose EQD

resultsThe maximum inter-observer deviation among all patients and all points ranged from 0.5 Gy to 24.1 Gy in EQD

conclusionsThere is a need to ensure consistency in vaginal points reporting. The impact of the dosimetric inter- and intra-observer variability should also be considered when dealing with dose tolerances and limits due to the potential dose gradient.

Indexed as

brachytherapycervixEMBRACE IIICRU 89inter-observer

Identifiers

PMID32395138
PMCPMC7207226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.